{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:51:39Z","timestamp":1791312699235,"version":"4.3.1"},"reference-count":81,"publisher":"Siapec Servizi Srl","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-245","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T07:02:21Z","timestamp":1625814141000},"page":"170-184","source":"Crossref","is-referenced-by-count":106,"title":["Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis"],"prefix":"10.32074","volume":"113","author":[{"given":"Samantha","family":"Sarcognato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Cazzagon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Cadamuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Cataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Covelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Guido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"10.32074\/1591-951X-245_ref1","doi-asserted-by":"crossref","unstructured":"Lazaridis KN, LaRusso NF. The cholangiopathies. Mayo Clin Proc 2015;90:791-800. https:\/\/doi.org\/10.1016\/j.mayocp.2015.03.017","DOI":"10.1016\/j.mayocp.2015.03.017"},{"key":"10.32074\/1591-951X-245_ref2","doi-asserted-by":"crossref","unstructured":"Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004;127:1565-1577. https:\/\/doi.org\/10.1053\/j.gastro.2004.08.006","DOI":"10.1053\/j.gastro.2004.08.006"},{"key":"10.32074\/1591-951X-245_ref3","doi-asserted-by":"crossref","unstructured":"Dalekos GN, Gatselis NK. Variant and specific forms of autoimmune cholestatic liver diseases. Arch Immunol Ther Exp (Warsz) 2019;67:197-211. https:\/\/doi.org\/10.1007\/s00005-019-00550-9","DOI":"10.1007\/s00005-019-00550-9"},{"key":"10.32074\/1591-951X-245_ref4","doi-asserted-by":"crossref","unstructured":"Harada K, Sato Y, Itatsu K, et al. Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia. Hepatology 2007;46:1146-1154. https:\/\/doi.org\/10.1002\/hep.21797","DOI":"10.1002\/hep.21797"},{"key":"10.32074\/1591-951X-245_ref5","doi-asserted-by":"crossref","unstructured":"Nakanuma Y, Zen Y. Pathology and immunopathology of immunoglobulin G4-related sclerosing cholangitis: the latest addition to the sclerosing cholangitis family. Hepatol Res 2007;37:S478-486. https:\/\/doi.org\/10.1111\/j.1872-034X.2007.00243.x","DOI":"10.1111\/j.1872-034X.2007.00243.x"},{"key":"10.32074\/1591-951X-245_ref6","doi-asserted-by":"crossref","unstructured":"Zen Y, H\u00fcbscher SG, Nakanuma Y. Bile duct diseases. In: Burt AD, Ferrell LD, H\u00fcbscher SG, eds. MacSween\u2019s pathology of the liver. 7th ed. Philadelphia, PA: Elsevier 2018, p. 515.","DOI":"10.1016\/B978-0-7020-6697-9.00009-1"},{"key":"10.32074\/1591-951X-245_ref7","doi-asserted-by":"crossref","unstructured":"Zhang W, Sharma R, Ju ST, et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology 2009;49:545-552. https:\/\/doi.org\/10.1002\/hep.22651","DOI":"10.1002\/hep.22651"},{"key":"10.32074\/1591-951X-245_ref8","doi-asserted-by":"crossref","unstructured":"Sasaki M, Ikeda H, Sawada S, et al. Naturally-occurring regulatory T cells are increased in inflamed portal tracts with cholangiopathy in primary biliary cirrhosis. J Clin Pathol 2007;60:1102-1107. https:\/\/doi.org\/10.1136\/jcp.2006.044776","DOI":"10.1136\/jcp.2006.044776"},{"key":"10.32074\/1591-951X-245_ref9","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145-172. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"10.32074\/1591-951X-245_ref10","doi-asserted-by":"crossref","unstructured":"Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015;386:1565-1575. https:\/\/doi.org\/10.1016\/S0140-6736(15)00154-3","DOI":"10.1016\/S0140-6736(15)00154-3"},{"key":"10.32074\/1591-951X-245_ref11","doi-asserted-by":"crossref","unstructured":"Chalifoux SL, Konyn PG, Saab S, et al. Extrahepatic manifestations of primary biliary cholangitis. Gut Liver 2017:11;771-780. https:\/\/doi.org\/10.5009\/gnl16365","DOI":"10.5009\/gnl16365"},{"key":"10.32074\/1591-951X-245_ref12","doi-asserted-by":"crossref","unstructured":"Floreani A, Cazzagon N. PBC and related extrahepatic diseases. Best Pract Res Clin Gastroenterol 2018;34-35:49-54. https:\/\/doi.org\/10.1016\/j.bpg.2018.05.013","DOI":"10.1016\/j.bpg.2018.05.013"},{"key":"10.32074\/1591-951X-245_ref13","doi-asserted-by":"crossref","unstructured":"Harms MH, van Buuren HR, van der Meer AJ, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2019;71:357-365. https:\/\/doi.org\/10.1016\/j.jhep.2019.04.001","DOI":"10.1016\/j.jhep.2019.04.001"},{"key":"10.32074\/1591-951X-245_ref14","doi-asserted-by":"crossref","unstructured":"Hirschfield GM, Dyson JK, Jones DEJ, et al. The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-1594. https:\/\/doi.org\/10.1136\/gutjnl-2017-315259","DOI":"10.1136\/gutjnl-2017-315259"},{"key":"10.32074\/1591-951X-245_ref15","doi-asserted-by":"crossref","unstructured":"Floreani A, Mangini C. Primary biliary cholangitis: old and novel therapy. Eur J Intern Med 2018;47:1-5. https:\/\/doi.org\/10.1016\/j.ejim.2017.06.020","DOI":"10.1016\/j.ejim.2017.06.020"},{"key":"10.32074\/1591-951X-245_ref16","doi-asserted-by":"crossref","unstructured":"Gao L, Wang L, Gershwin ME, et al. Clinical management of primary biliary cholangitis - Strategies and evolving trends. Clin Rev Allergy Immunol 2020;59:175-194. https:\/\/doi.org\/10.1007\/s12016-019-08772-7","DOI":"10.1007\/s12016-019-08772-7"},{"key":"10.32074\/1591-951X-245_ref17","doi-asserted-by":"crossref","unstructured":"Lammers WJ, Hirschfield GM, Corpechot C, et al. on behalf of the Global PBC Study Group. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015;149:1804-1812.e4. https:\/\/doi.org\/10.1053\/j.gastro.2015.07.061","DOI":"10.1053\/j.gastro.2015.07.061"},{"key":"10.32074\/1591-951X-245_ref18","doi-asserted-by":"crossref","unstructured":"Carbone M, Sharp SJ, Flack S, et al. on behalf of the UK-PBC Consortium. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016;63:930-950. https:\/\/doi.org\/10.1002\/hep.28017","DOI":"10.1002\/hep.28017"},{"key":"10.32074\/1591-951X-245_ref19","doi-asserted-by":"crossref","unstructured":"Alvaro D, Carpino G, Invernizzi P, et al. Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. Liver Int 2020;40:2590-2601. https:\/\/doi.org\/10.1111\/liv.14627","DOI":"10.1111\/liv.14627"},{"key":"10.32074\/1591-951X-245_ref20","doi-asserted-by":"crossref","unstructured":"Tsuneyama K, Baba H, Ogawa H, et al. Primary biliary cholangitis: its pathological characteristics and immunopathological mechanisms. J Med Invest 2017;64:7-13. https:\/\/doi.org\/10.2152\/jmi.64.7","DOI":"10.2152\/jmi.64.7"},{"key":"10.32074\/1591-951X-245_ref21","doi-asserted-by":"crossref","unstructured":"Terziroli Beretta-Piccoli B, Mieli-Vergani G, Gershwin ME, et al. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun 2019;105:102328. https:\/\/doi.org\/10.1016\/j.jaut.2019.102328","DOI":"10.1016\/j.jaut.2019.102328"},{"key":"10.32074\/1591-951X-245_ref22","doi-asserted-by":"crossref","unstructured":"Yokoda RT, Rodriguez EA. Review: Pathogenesis of cholestatic liver diseases. World J Hepatol 2020;12:423-435. https:\/\/doi.org\/10.4254\/wjh.v12.i8.423","DOI":"10.4254\/wjh.v12.i8.423"},{"key":"10.32074\/1591-951X-245_ref23","doi-asserted-by":"crossref","unstructured":"Yan C, Koda S, Wu J, et al. Roles of trained immunity in the pathogenesis of cholangiopathies: a therapeutic target. Hepatology 2020;72:1838-1850. https:\/\/doi.org\/10.1002\/hep.31395","DOI":"10.1002\/hep.31395"},{"key":"10.32074\/1591-951X-245_ref24","doi-asserted-by":"crossref","unstructured":"Banales JM, Huebert RC, Gores GJ, et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol 2019;16:269-281. doi:10.1038\/s41575-019-0125-y","DOI":"10.1038\/s41575-019-0125-y"},{"key":"10.32074\/1591-951X-245_ref25","doi-asserted-by":"crossref","unstructured":"Ronca V, Mancuso C, Invernizzi P, et al. Immune system and cholangiocytes: a puzzling affair in primary biliary cholangitis. J Leukoc Biol 2020;108:659-671. https:\/\/doi.org\/10.1002\/JLB.5MR0320-200R","DOI":"10.1002\/JLB.5MR0320-200R"},{"key":"10.32074\/1591-951X-245_ref26","unstructured":"Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis: chronic non-suppurative destructive cholangitis. Am J Pathol 1965;46:387-407."},{"key":"10.32074\/1591-951X-245_ref27","doi-asserted-by":"crossref","unstructured":"Nakanuma Y, Harada K. Florid duct lesion in primary biliary cirrhosis shows highly proliferative activities. J Hepatol 1993;19:216-221. https:\/\/doi.org\/10.1016\/s0168-8278(05)80574-4","DOI":"10.1016\/S0168-8278(05)80574-4"},{"key":"10.32074\/1591-951X-245_ref28","doi-asserted-by":"crossref","unstructured":"Carpino G, Cardinale V, Gaudio E, et al. Hepatic stem\/progenitor cell activation differs between primary sclerosing and primary biliary cholangitis. Am J Pathol 2018;188:627-639. https:\/\/doi.org\/10.1016\/j.ajpath.2017.11.010","DOI":"10.1016\/j.ajpath.2017.11.010"},{"key":"10.32074\/1591-951X-245_ref29","doi-asserted-by":"crossref","unstructured":"Takahashi T, Miura T, Nakamura J, et al. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology 2012; 55:846-855. https:\/\/doi.org\/10.1002\/hep.24757","DOI":"10.1002\/hep.24757"},{"key":"10.32074\/1591-951X-245_ref30","doi-asserted-by":"crossref","unstructured":"Nakanuma Y, Hoso M, Mizuno Y, et al. Pathologic study of primary biliary cirrhosis of early histologic stages presenting cholestatic jaundice. Liver 1988;8:319-324. https:\/\/doi.org\/10.1111\/j.1600-0676.1988.tb01010.x","DOI":"10.1111\/j.1600-0676.1988.tb01010.x"},{"key":"10.32074\/1591-951X-245_ref31","doi-asserted-by":"crossref","unstructured":"Theise ND, Crawford JM, Nakanuma Y, et al. Canal of Hering loss is an initiating step for primary biliary cholangitis (PBC): a hypothesis. Med Hypotheses 2020;140:109680. https:\/\/doi.org\/10.1016\/j.mehy.2020.109680","DOI":"10.1016\/j.mehy.2020.109680"},{"key":"10.32074\/1591-951X-245_ref32","doi-asserted-by":"crossref","unstructured":"Khan FM, Komarla AR, Mendoza PG, et al. Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: \u201cminimal change PBC\u201d? Hepatology 2013;57:700-707. https:\/\/doi.org\/10.1002\/hep.26020","DOI":"10.1002\/hep.26020"},{"key":"10.32074\/1591-951X-245_ref33","doi-asserted-by":"crossref","unstructured":"Kakuda Y, Harada K, Nakanuma Y. Canals of Hering loss relates to the progression of the histological stages of primary biliary cirrhosis. J Clin Pathol 2015;68:141-147. https:\/\/doi.org\/10.1136\/jclinpath-2014-202417","DOI":"10.1136\/jclinpath-2014-202417"},{"key":"10.32074\/1591-951X-245_ref34","doi-asserted-by":"crossref","unstructured":"Colina F, Pinedo F, Nevado M, et al. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology 1992;102:1319-1324.","DOI":"10.1016\/0016-5085(92)90771-P"},{"key":"10.32074\/1591-951X-245_ref35","doi-asserted-by":"crossref","unstructured":"Nakanuma Y, Hirata K. Unusual hepatocellular lesions in primary biliary cirrhosis resembling but unrelated to hepatocellular neoplasms. Virchows Arch A Pathol Anat Histopathol 1993;422:17-23. https:\/\/doi.org\/10.1007\/BF01605128","DOI":"10.1007\/BF01605128"},{"key":"10.32074\/1591-951X-245_ref36","doi-asserted-by":"crossref","unstructured":"Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-112. https:\/\/doi.org\/10.1007\/BF00432479","DOI":"10.1007\/BF00432479"},{"key":"10.32074\/1591-951X-245_ref37","doi-asserted-by":"crossref","unstructured":"Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967;60:1257-1260","DOI":"10.1177\/003591576706001205"},{"key":"10.32074\/1591-951X-245_ref38","doi-asserted-by":"crossref","unstructured":"Harada K, Hsu M, Nakanuma Y, et al. Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol 2013;47:174-181. https:\/\/doi.org\/10.1097\/MCG.0b013e31827234e4","DOI":"10.1097\/MCG.0b013e31827234e4"},{"key":"10.32074\/1591-951X-245_ref39","doi-asserted-by":"crossref","unstructured":"Kakuda Y, Harada K, Sawada-Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol 2013;44:1107-1117. https:\/\/doi.org\/10.1016\/j.humpath.2012.09.017","DOI":"10.1016\/j.humpath.2012.09.017"},{"key":"10.32074\/1591-951X-245_ref40","doi-asserted-by":"crossref","unstructured":"Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34:659-665. https:\/\/doi.org\/10.1053\/jhep.2001.27562","DOI":"10.1053\/jhep.2001.27562"},{"key":"10.32074\/1591-951X-245_ref41","doi-asserted-by":"crossref","unstructured":"Verdonk RC, Lozano MF, Gouw ASH, et al. Bile ductal injury and ductular reaction are frequent phenomena with different significance in autoimmune hepatitis. Liver Int 2016;36:1362-1369. https:\/\/doi.org\/10.1111\/liv.13083","DOI":"10.1111\/liv.13083"},{"key":"10.32074\/1591-951X-245_ref42","doi-asserted-by":"crossref","unstructured":"Balitzer D, Shafizadeh N, Kakar S, et al. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol 2017;30:773-783. https:\/\/doi.org\/10.1038\/modpathol.2016.267","DOI":"10.1038\/modpathol.2016.267"},{"key":"10.32074\/1591-951X-245_ref43","doi-asserted-by":"crossref","unstructured":"Goet JC, Harms MH, Hansen BE, et al. Risk stratification and prognostic modelling in primary biliary cholangitis. Best Pract Res Clin Gastroenterol 2018;34-35:95-106. https:\/\/doi.org\/10.1016\/j.bpg.2018.06.006","DOI":"10.1016\/j.bpg.2018.06.006"},{"key":"10.32074\/1591-951X-245_ref44","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Kakuda Y, Harada K, et al. Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis. World J Gastroenterol 2014;20:3597-3608. https:\/\/doi.org\/10.3748\/wjg.v20.i13.3597","DOI":"10.3748\/wjg.v20.i13.3597"},{"key":"10.32074\/1591-951X-245_ref45","doi-asserted-by":"crossref","unstructured":"Tan D, Goodman ZD. Liver biopsy in primary biliary cholangitis: indications and interpretation. Clin Liver Dis 2018;22:579-588. https:\/\/doi.org\/10.1016\/j.cld.2018.03.008","DOI":"10.1016\/j.cld.2018.03.008"},{"key":"10.32074\/1591-951X-245_ref46","doi-asserted-by":"crossref","unstructured":"Karlsen TH, Folseraas T, Vesterhus M, et al. Primary sclerosing cholangitis - a comprehensive review. J Hepatol 2017;67:1298-1323. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.022","DOI":"10.1016\/j.jhep.2017.07.022"},{"key":"10.32074\/1591-951X-245_ref47","doi-asserted-by":"crossref","unstructured":"Hirschfield GM, Karlsen TH, Adams DH, et al. Primary sclerosing cholangitis. Lancet 2013;382:1587-1599. https:\/\/doi.org\/10.1016\/S0140-6736(13)60096-3","DOI":"10.1016\/S0140-6736(13)60096-3"},{"key":"10.32074\/1591-951X-245_ref48","doi-asserted-by":"crossref","unstructured":"Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med 2016;375:1161-1170. https:\/\/doi.org\/10.1056\/NEJMra1506330","DOI":"10.1056\/NEJMra1506330"},{"key":"10.32074\/1591-951X-245_ref49","doi-asserted-by":"crossref","unstructured":"Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000;32:182-187. https:\/\/doi.org\/10.1016\/s0168-8278(00)80061-6","DOI":"10.1016\/S0168-8278(00)80061-6"},{"key":"10.32074\/1591-951X-245_ref50","doi-asserted-by":"crossref","unstructured":"Lindor KD, Kowdley KV, Harrison ME. ACG Clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015;110:646-659. https:\/\/doi.org\/10.1038\/ajg.2015.112","DOI":"10.1038\/ajg.2015.112"},{"key":"10.32074\/1591-951X-245_ref51","doi-asserted-by":"crossref","unstructured":"Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 2019;68:1356-1378. https:\/\/doi.org\/10.1136\/gutjnl-2018-317993","DOI":"10.1136\/gutjnl-2018-317993"},{"key":"10.32074\/1591-951X-245_ref52","doi-asserted-by":"crossref","unstructured":"Aabakken L, Karlsen TH, Hassan C, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) clinical guideline. Endoscopy 2017;49:588-608. https:\/\/doi.org\/10.1055\/s-0043-107029","DOI":"10.1055\/s-0043-107029"},{"key":"10.32074\/1591-951X-245_ref53","doi-asserted-by":"crossref","unstructured":"Kim WR, Therneau TM, Dickson ER, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688-694. https:\/\/doi.org\/10.4065\/75.7.688","DOI":"10.4065\/75.7.688"},{"key":"10.32074\/1591-951X-245_ref54","doi-asserted-by":"crossref","unstructured":"de Vries EM, Wang J, Ponsioen CY, et al. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut 2018;67:1864-1869. https:\/\/doi.org\/10.1136\/gutjnl-2016-313681","DOI":"10.1136\/gutjnl-2016-313681"},{"key":"10.32074\/1591-951X-245_ref55","unstructured":"Iravani S, Dooghaie-Moghadam A, Razavi-Khorasani N, et al. An update on treatment options for primary sclerosing cholangitis. Gastroenterol Hepatol Bed Bench 2020;13:115-124."},{"key":"10.32074\/1591-951X-245_ref56","doi-asserted-by":"crossref","unstructured":"Dean G, Hanauer S, Levitsky J. The role of the intestine in the pathogenesis of primary sclerosing cholangitis: evidence and therapeutic implications. Hepatology 2020;72:1127-1138. https:\/\/doi.org\/10.1002\/hep.31311","DOI":"10.1002\/hep.31311"},{"key":"10.32074\/1591-951X-245_ref57","doi-asserted-by":"crossref","unstructured":"Shah A, Macdonald GA, Morrison M, et al. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework. Am J Gastroenterol 2020;115:814-822. https:\/\/doi.org\/10.14309\/ajg.0000000000000604","DOI":"10.14309\/ajg.0000000000000604"},{"key":"10.32074\/1591-951X-245_ref58","doi-asserted-by":"crossref","unstructured":"Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology 2012;60:236-248. https:\/\/doi.org\/10.1111\/j.1365-2559.2011.03853.x","DOI":"10.1111\/j.1365-2559.2011.03853.x"},{"key":"10.32074\/1591-951X-245_ref59","doi-asserted-by":"crossref","unstructured":"Colling R, Verrill C, Fleming K, et al. Bile duct basement membrane thickening in primary sclerosing cholangitis. Histopathology 2016;68:819-824. https:\/\/doi.org\/10.1111\/his.12857","DOI":"10.1111\/his.12857"},{"key":"10.32074\/1591-951X-245_ref60","doi-asserted-by":"crossref","unstructured":"Fiel MI, Sima HR, Schiano TD, et al. A morphometric study of the hepatic arterioles in end-stage primary sclerosing cholangitis. Virchows Arch 2015;466:143-149. https:\/\/doi.org\/10.1007\/s00428-014-1680-9","DOI":"10.1007\/s00428-014-1680-9"},{"key":"10.32074\/1591-951X-245_ref61","doi-asserted-by":"crossref","unstructured":"Carrasco-Avino G, Thomas D Schiano TD, Fiel MI, et al. Primary sclerosing cholangitis: detailed histologic assessment and integration using bioinformatics highlights arterial fibrointimal hyperplasia as a novel feature. Am J Clin Pathol 2015;143:505-513. https:\/\/doi.org\/10.1309\/AJCPVKFVIPRBXQR2","DOI":"10.1309\/AJCPVKFVIPRBXQR2"},{"key":"10.32074\/1591-951X-245_ref62","doi-asserted-by":"crossref","unstructured":"de Vries EM, de Krijger M, Ponsioen CY, et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study. Hepatology 2017;65:907-919. https:\/\/doi.org\/10.1002\/hep.28963","DOI":"10.1002\/hep.28963"},{"key":"10.32074\/1591-951X-245_ref63","doi-asserted-by":"crossref","unstructured":"Boberg KM, Chapman RW, Hirschfield GM, et al., International Autoimmune Hepatitis Group. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-385. https:\/\/doi.org\/10.1016\/j.jhep.2010.09.002","DOI":"10.1016\/j.jhep.2010.09.002"},{"key":"10.32074\/1591-951X-245_ref64","doi-asserted-by":"crossref","unstructured":"Kuiper EMM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010;8:530-534. https:\/\/doi.org\/10.1016\/j.cgh.2010.03.004","DOI":"10.1016\/j.cgh.2010.03.004"},{"key":"10.32074\/1591-951X-245_ref65","doi-asserted-by":"crossref","unstructured":"Chazouilleres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301. https:\/\/doi.org\/10.1002\/hep.510280203","DOI":"10.1002\/hep.510280203"},{"key":"10.32074\/1591-951X-245_ref66","doi-asserted-by":"crossref","unstructured":"Wang Q, Selmi C, Zhou X, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun 2013;41:140-145. https:\/\/doi.org\/10.1016\/j.jaut.2012.10.004","DOI":"10.1016\/j.jaut.2012.10.004"},{"key":"10.32074\/1591-951X-245_ref67","doi-asserted-by":"crossref","unstructured":"Zhang W, De D, Bacon BR, et al. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome. Hepatol Commun 2018;2:245-253. https:\/\/doi.org\/10.1002\/hep4.1148","DOI":"10.1002\/hep4.1148"},{"key":"10.32074\/1591-951X-245_ref68","doi-asserted-by":"crossref","unstructured":"Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver (HASL) clinical practice guidelines: autoimmune hepatitis. Ann Gastroenterol 2019;32:1-23. https:\/\/doi.org\/10.20524\/aog.2018.0330","DOI":"10.20524\/aog.2018.0330"},{"key":"10.32074\/1591-951X-245_ref69","doi-asserted-by":"crossref","unstructured":"Lee H, Stapp RT, Shah VV, et al. The usefulness of IgG and IgM immunostaining of periportal inflammatory cells (plasma cells and lymphocytes) for the distinction of autoimmune hepatitis and primary biliary cirrhosis and their staining pattern in autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Am J Clin Pathol 2010;133:430-437. https:\/\/doi.org\/10.1309\/AJCPE93GZSHUNTAI","DOI":"10.1309\/AJCPE93GZSHUNTAI"},{"key":"10.32074\/1591-951X-245_ref70","doi-asserted-by":"crossref","unstructured":"Abe K, Takahashi A, Nozawa Y, et al. The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases. Med Mol Morphol 2014;47:162-168. https:\/\/doi.org\/10.1007\/s00795-014-0082-z","DOI":"10.1007\/s00795-014-0082-z"},{"key":"10.32074\/1591-951X-245_ref71","doi-asserted-by":"crossref","unstructured":"Yang F, Wang O, Wang Z, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol 2016;50:114-123. https:\/\/doi.org\/10.1007\/s12016-015-8516-5","DOI":"10.1007\/s12016-015-8516-5"},{"key":"10.32074\/1591-951X-245_ref72","doi-asserted-by":"crossref","unstructured":"Ozaslan E, Efe C, Heurgue-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol 2014;12:863-869. https:\/\/doi.org\/10.1016\/j.cgh.2013.09.021","DOI":"10.1016\/j.cgh.2013.09.021"},{"key":"10.32074\/1591-951X-245_ref73","doi-asserted-by":"crossref","unstructured":"Zhang H, Li S, Yang J, et al. A meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBC-AIH-overlap syndrome: evidence from 97 monotherapy and 117 combinations. Prz Gastroenterol 2015;10:148-155. https:\/\/doi.org\/10.5114\/pg.2015.51187","DOI":"10.5114\/pg.2015.51187"},{"key":"10.32074\/1591-951X-245_ref74","doi-asserted-by":"crossref","unstructured":"Deneau MR, El-Matary W, Valentino PL, et al. The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration. Hepatology 2017;66:518-527. https:\/\/doi.org\/10.1002\/hep.29204","DOI":"10.1002\/hep.29204"},{"key":"10.32074\/1591-951X-245_ref75","doi-asserted-by":"crossref","unstructured":"Weism\u00fcller TJ, Trivedi PJ, Bergquist A, et al., International PSC Study Group. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152:1975-1984.e8. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.038","DOI":"10.1053\/j.gastro.2017.02.038"},{"key":"10.32074\/1591-951X-245_ref76","doi-asserted-by":"crossref","unstructured":"Olsson R, Glaumann H, Almer S, et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009;20:190-196. https:\/\/doi.org\/10.1016\/j.ejim.2008.06.004","DOI":"10.1016\/j.ejim.2008.06.004"},{"key":"10.32074\/1591-951X-245_ref77","doi-asserted-by":"crossref","unstructured":"Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-553. https:\/\/doi.org\/10.1053\/jhep.2001.22131","DOI":"10.1053\/jhep.2001.22131"},{"key":"10.32074\/1591-951X-245_ref78","doi-asserted-by":"crossref","unstructured":"Rojas CP, Bodicharla R, Campuzano-Zuluanga G, et al. Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents. Fetal Pediatr Pathol 2014;33:202-209. https:\/\/doi.org\/10.3109\/15513815.2014.898721","DOI":"10.3109\/15513815.2014.898721"},{"key":"10.32074\/1591-951X-245_ref79","doi-asserted-by":"crossref","unstructured":"Oliveira EMG, Oliveira PM, Becker V, et al. Overlapping of primary biliary cirrhosis and small duct primary sclerosing cholangitis: first case report. J Clin Med Res 2012;4:429-433. https:\/\/doi.org\/10.4021\/jocmr1060w","DOI":"10.4021\/jocmr1060w"},{"key":"10.32074\/1591-951X-245_ref80","doi-asserted-by":"crossref","unstructured":"Floreani A, Motta R, Cazzagon N, et al. The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. Dig Liver Dis 2015;47:432-435. https:\/\/doi.org\/10.1016\/j.dld.2015.02.002","DOI":"10.1016\/j.dld.2015.02.002"},{"key":"10.32074\/1591-951X-245_ref81","doi-asserted-by":"crossref","unstructured":"Sundaram S, S K, Mazumdar S, et al. Overlap syndrome between primary biliary cholangitis and primary sclerosing cholangitis. ACG Case Rep J 2018;5:e54. https:\/\/doi.org\/10.14309\/crj.2018.54","DOI":"10.14309\/crj.2018.54"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T08:25:38Z","timestamp":1730795138000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.pathologica.it\/article\/view\/245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-245","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"article-number":"3"}}